Table 1.
Baseline characteristics of randomized subjects
| Placebo | Fenofibrate | CoQ | Combination | |
|---|---|---|---|---|
| n | 20 | 19 | 16 | 19 |
| Age (years) | 62.4 ± 8.8 | 64.8 ± 7.3 | 61.3 ± 4.1 | 63.0 ± 9.4 |
| Male/female (n) | 14/6 | 13/6 | 13/3 | 13/6 |
| BMI (kg/m2) | 30.7 ± 5.0 | 29.9 ± 5.6 | 30.1 ± 4.6 | 28.7 ± 3.4 |
| Fasting glucose (mmol/l) | 7.2 ± 1.8 | 7.0 ± 1.1 | 7.6 ± 1.6 | 7.6 ± 2.2 |
| GHb (%) | 6.5 ± 1.0 | 6.5 ± 0.9 | 6.6 ± 0.9 | 6.6 ± 0.8 |
| Duration of type 2 diabetes (years) | 5.5 (4.1–7.5) | 4.5 (2.7–7.5) | 3.1 (1.8–5.4) | 3.0 (2.0–4.9) |
| Resting SBP (mmHg) | 130.5 ± 15.7 | 131.0 ± 17.8 | 136.8 ± 14.7 | 132.8 ± 17.3 |
| Resting DBP (mmHg) | 73.0 ± 11.8 | 73.3 ± 10.4 | 76.9 ± 10.0 | 74.1 ± 9.2 |
| Total cholesterol (mmol/l) | 4.4 ± 1.2 | 4.6 ± 0.9 | 4.6 ± 0.9 | 4.6 ± 0.8 |
| Triglycerides (mmol/l) | 1.6 ± 0.7 | 1.6 ± 1.0 | 1.7 ± 0.7 | 1.7 ± 0.8 |
| HDL cholesterol (mmol/l) | 1.22 ± 0.27 | 1.29 ± 0.36 | 1.25 ± 0.25 | 1.35 ± 0.38 |
| LDL cholesterol (mmol/l) | 2.5 ± 1.1 | 2.6 ± 0.7 | 2.6 ± 0.8 | 2.5 ± 0.7 |
| Serum creatinine (umol/l) | 82 ± 16 | 74 ± 10 | 79 ± 15 | 75 ± 15 |
| History of ischemic heart disease | 15.0 | 15.8 | 12.5 | 10.5 |
| LV hypertrophy | 20.0 | 26.3 | 6.3 | 10.5 |
| LVDD: mild/moderate (n) | 16/4 | 17/2 | 15/1 | 16/3 |
| Medications | ||||
| No antihyperglycemic medication | 25.0 | 42.1 | 43.8 | 26.3 |
| Metformin | 60.0 | 47.4 | 50.0 | 68.4 |
| Sulphonylurea | 50.0 | 42.1 | 37.5 | 21.1 |
| Nocturnal basal insulin | 5.0 | 10.5 | 6.3 | 0.0 |
| No antihypertensive medication | 35.0 | 63.2 | 50.0 | 63.2 |
| ACE inhibitor | 45.0 | 26.3 | 37.5 | 15.8 |
| Angiotensin receptor blocker | 15.0 | 10.5 | 6.3 | 5.3 |
| β-Adrenergic receptor blocker | 5.0 | 5.3 | 25.0 | 10.5 |
| Calcium channel blocker | 25.0 | 15.8 | 18.8 | 10.5 |
| Diuretic | 30.0 | 10.5 | 18.8 | 10.5 |
| Statin | 75.0 | 36.8 | 68.8 | 52.6 |
Data are means ± SD, percent, or geometric means (95% CI).